Ask AI

Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Tool
Tool

Released: October 30, 2026

See Activity Collection

The expanding range of JAK inhibitor options in myelofibrosis has increased the need for individualized treatment decisions that account for disease characteristics, molecular findings, prior therapy, comorbidities, cytopenias, symptoms, and patient-specific goals. This Interactive Decision Support Tool applies key patient and disease characteristics to treatment selections and compares their intended approach with recommendations from MF experts, exploring how clinical evidence, supportive care needs, and patient factors can inform personalized, equitable management across diverse patient populations.

MF Treatment Tool

With just a few clicks, get expert treatment recommendations for your patient with myelofibrosis.

To begin, answer a few quick questions below about your actual or hypothetical patient. Then, we’ll show how your approach compares with the expert panel’s.

Interactive Decision Support Tool

Program Content